Search results
Results From The WOW.Com Content Network
Tegafur/gimeracil/oteracil, sold under the brand name Teysuno among others is a fixed-dose combination medication used for the treatment of advanced gastric cancer when used in combination with cisplatin, [3] and also for the treatment of head and neck cancer, colorectal cancer, non–small-cell lung, breast, pancreatic, and biliary tract cancers.
Hence, all GISTs are eligible for cancer staging in the AJCC (7th edition) / UICC. [8] Nonetheless, different GISTs have different risk assessments of their tendency to recur or to metastasize, dependent on their site of origin, size, and number of mitotic figures.
Vincent Theodore DeVita Jr. (born March 7, 1935) is the Amy and Joseph Perella Professor of Medicine at Yale Cancer Center, and a Professor of Epidemiology and Public Health. He directed the Yale Cancer Center from 1993 to 2003. [1] He has been president of the board of directors of the American Cancer Society (2012-2013).
big.assets.huffingtonpost.com
George P. Canellos is an American oncologist and cancer researcher. His research career spans many decades, as well as several areas of therapeutic agents for the treatment of malignant diseases. His research career spans many decades, as well as several areas of therapeutic agents for the treatment of malignant diseases.
It was developed at the National Cancer Institute in the 1960s by a team that included Vincent DeVita, Jr. Although no longer the most effective combination, MOPP is still used after relapse or where the patient has certain allergies or lung or heart problems which prevents the use of another regimen.
Steven A. Rosenberg (born 2 August 1940 [1]) is an American cancer researcher and surgeon, chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences.
Esophageal cancer is the eighth-most frequently-diagnosed cancer worldwide, [2] and because of its poor prognosis, it is the sixth most-common cause of cancer-related deaths. [55] It caused about 400,000 deaths in 2012, accounting for about 5% of all cancer deaths (about 456,000 new cases were diagnosed, representing about 3% of all cancers). [2]